For example, Radu, Pichon [11] discovered the FSH receptor to not be expressed in normal tissue located more than 10 mm from multiple tumors studied, including ovarian carcinomas, thereby supporting the hypothesis of applying theranostics targeting the FSH receptor to solely attack malignant tissue [11,12,13]. Here, FSHR is linked to ovarian carcinoma.